Regeneron Pharmaceuticals, Inc.
published promising results from multiple Phase 3 trials including a
breakthrough allergy drug and a therapy offering significant
fat loss in comparison to existing treatments. Additionally, the
standard GLP-1 Weight Loss and the
Cat and Birch Allergies trials seem to advance the company's allergy pipeline. The FDA has extended review deadlines for two of Regeneron's submissions. Furthermore, Regeneron has been the subject of notable activity from various investment institutes, with several buying into and others scaling down their holdings in Regeneron. While its stock has seen a slip of
21.1% year to date, several sources, such as BMO Capital and Evercore ISI, maintain a
buy rating on Regeneron and predict a target price as high as $750-$815. The company achieved regulatory approval for Dupixent® from the U.S FDA and also acquired 23andme assets for $256 million. Moreover, the breakthrough drug for ultra-rare FOP Disease shows potential in preventing
99% bone formation.
Regeneron Pharmaceuticals REGN News Analytics from Wed, 07 May 2025 07:00:00 GMT to Sat, 20 Sep 2025 10:29:11 GMT -
Rating 6
- Innovation 4
- Information 6
- Rumor -2
